Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Brentuximab Vedotin in R/R cHL (CheckMate 744)
NCT02927769Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2017
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 2, open-label trial of nivolumab in classic Hodgkin lymphoma (cHL) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Complete Metabolic Response Rate up to 18 weeks and Event-free Survival at 3 years. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
classic Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT02927769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02927769.